Biotechnology Market Research Reports & Consulting

Market Reports

• Bioburden Testing Market by Product (Consumables, Instrument (PCR, Microscope)), Test (Anerobic, Mold/Fungi, Aerobic, Spore), Application (Raw Material, Medical Devices, Sterility Testing), End User (Pharma, Biotechnology, CMO) - Global Forecast to 2023

  The bioburden testing market is projected to reach USD 1,103 million by 2023 from USD 614 million in 2018, at a CAGR of 12.4% during the forecast period. Growth in this market can be attributed to factors such as the growth in the medical devices, pharmaceutical, and biotechnology industries; rising safety concerns related to food and beverage products; and the increasing number of product recalls due to microbial contamination. However, the high cost of enumeration instruments is expected to restrain market growth in the coming years. The bioburden testing market is competitive in nature, with the presence of several large and small players. Charles River (US), Merck KGaA (Germany), SGS SA (Switzerland), WuXi AppTec (China), Becton, Dickinson and Company (US), NAMSA (US), Nelson Laboratories, LLC (US), Thermo Fisher Scientific (US), biomérieux SA (France), and Pacific BioLabs (US) are some of the leading payers in the bioburden testing market.

  • Published: December 2018
  • Price: $ 5650
  • TOC Available:

• Synthetic Stem Cells Market by Application (Cardiovascular Disease, Neurological Disorders, Other Applications (Cancer, Diabetes, Gastrointestinal, Musculoskeletal Disorders)), Region (North America (US, Canada), Europe, APAC, RoW) - Global Forecast to 2028

  The market size for synthetic stem cells is expected to grow from USD 14 million in 2023 to USD 37 million by 2028, at a CAGR of 22.5% during the forecast period. The ethical concerns on the use of embryonic stem cells and the risk of tumor formation and immune response to natural stem cells are the key factors driving the growth of this market. The key developers of synthetic stem cell technology are North Carolina State University (NCSU) (US) and Zhengzhou University (China).

  • Published: December 2018
  • Price: $ 5650
  • TOC Available:

• Gel Documentation Systems Market by Product (Instruments (Digital), Software), Light Source (Laser, LED, UV), Detection (Chemiluminescence), Application (Nucleic Acid), End User (Academic Institutes, Biotechnology Companies) - Global Forecast to 2023

  The gel documentation systems market is projected to grow from USD 258 million in 2018 to USD 304 million by 2023, at a CAGR of 3.3% during the forecast period. Growth in the gel documentation systems market is mainly driven by the increasing prevalence of infectious and chronic disease, and rising research & development expenditure in the pharmaceutical and biotechnology companies. The major players in the gel documentation systems market are GE Healthcare (US), Bio-Rad Laboratories, inc. (US), Thermo Fisher Scientific (US), LI-COR Biosciences (US), Endress+Hauser Management AG (Switzerland), Vilber Lourmat (France), Scientific Digital Imaging plc (UK), Bio-Techne (US), Cleaver Scientific (US), and Azure Biosystems (US).

  • Published: December 2018
  • Price: $ 5650
  • TOC Available:

• Genotyping Assay Market by Technology (PCR, Sequencing, Microarray, Electrophoresis, MALDI-TOF), Application (Pharmacogenomics, Diagnostic Research, Animal Genetics, Agricultural Biotechnology), and Product - Global Forecast to 2023

  The global genotyping assay market is projected to reach USD 31.9 billion by 2023 from USD 11.8 billion in 2018, at a CAGR of 22.0%. The growth of this market is mainly driven by technological advancements, the decreasing prices of DNA sequencing, and the increasing incidence of genetic diseases. The prominent players in the genotyping market are Thermo Fisher Scientific (US), Illumina (US), QIAGEN (Netherlands), Agilent Technologies (US), Danaher Corporation (US), Roche Diagnostics (Switzerland), GE Healthcare (US), Fluidigm Corporation (US), PerkinElmer (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories (US), Pacific Biosciences of California (US), GENEWIZ (US), and Integrated DNA Technologies (US).

  • Published: November 2018
  • Price: $ 5650
  • TOC Available:

• Protein Sequencing Market by Product (Sample Preparation, MS, Sequencer, Reagent, Consumable), Service, Technology (MS, Edman), Application (Biotherapeutics, Genetic Engineering), Enduser (Academia, Pharma, Biotechnology, CROs) - Global Forecast to 2023

  The protein sequencing market is projected to grow from an estimated USD 925 million in 2018 to USD 1,088 million by 2023, at a CAGR of 3.3% during the forecast period. Growth in the protein sequencing market is mainly driven by the increasing focus on target-based drug development by pharmaceutical and biotechnology companies, advancements in clinical Mass Spectrometry and analytical techniques, and increasing public-private financial support for proteomic research. Some of the prominent players in the protein sequencing market include Shimadzu (Japan), Thermo Fisher Scientific Inc. (US), SGS S.A. (Switzerland), Waters Corporation (US), Rapid Novor (Canada), Agilent Technologies (US), Charles River Laboratories (US) and Selvita (Poland).

  • Published: November 2018
  • Price: $ 5650
  • TOC Available:

• CRISPR Technology Market by Product (Enzymes, Kits, gRNA, Libraries, Design Tools), Service (gRNA Design, Cell Line Engineering), Application (Biomedical, Agricultural), End User (Pharma & Biopharma Companies, Academics, CROs) - Global Forecast to 2023

  The market for CRISPR technology is expected to grow from USD 562 million in 2018 to USD 1,715 million by 2023, at a CAGR of 25% during the forecast period. The rise in the availability of government and private funding and the adoption of CRISPR technology are the key factors driving the growth of this market. Some of the key players of CRISPR in this region are Cellecta, Inc. (US), Thermo Fisher (US), GeneCopoeia, Inc. (US), Applied StemCell (US), Synthego Corporation (US), OriGene Technologies (US), Horizon Discovery (UK), Merck (Germany), and GenScript (US).

  • Published: November 2018
  • Price: $ 5650
  • TOC Available:

• Apoptosis Assays Market by Product (Caspase, Annexin V, DNA Fragmentation, Mitochondrial Assay), Detection Technology (Flow Cytometry, Florescence microscopy), Application (Stem Cell, Discovery & Development, Clinical Research) - Global Forecast to 2023

  The global apoptosis assays market is projected to reach USD 5.9 billion by 2023 from USD 3.6 billion in 2018, at a CAGR of 10.5%. The prominent players in the apoptosis assays market are Merck KGaA (Germany), Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), Becton, Dickinson and Company (US), GE Healthcare (US), Sartorius AG (Germany), Danaher Corporation (US), Geno Technology (US), GeneCopoeia, Inc. (US), Bio-Techne Corporation(US), BioTek Instruments (US), PerkinElmer (US), Promega Corporation (US), Biotium (US), Abcam plc (UK), Canvax (Spain), Abnova (Taiwan), and Creative Bioarray (US).

  • Published: November 2018
  • Price: $ 5650
  • TOC Available:

• Gene Expression Analysis Market by Product and Services (Consumables (Reagents, DNA chips), Instruments (PCR, NGS), Services (Gene Expression Profiling)), End User (Pharma and Biotech Companies, Research Centers) - Global Forecasts to 2023

  The market for gene expression analysis market is expected to grow from USD 3.2 billion in 2018 to USD 4.9 billion by 2023, at a Compound Annual Growth Rate (CAGR) of 8.8% during the forecast period. The major players operating in the gene expression analysis market include Illumina, Inc. (US), Thermo Fisher Scientific, Inc. (US), and Bio-Rad Laboratories, Inc. (US) are the key players in the gene expression analysis market. Other players involved in this market are F. Hoffmann-La Roche Ltd. (Switzerland), GE Healthcare (UK), Pacific Biosciences of California, Inc. (US), BGI (China), PerkinElmer (US), Agilent Technologies Inc. (US), and QIAGEN N. V. (Netherlands), among others.

  • Published: November 2018
  • Price: $ 5650
  • TOC Available:

• Desalting and Buffer Exchange Market by Product (Kit, Cassette & Cartridge, Spin Columns), Technique (Size Exclusion Chromatography, Filtration, Dialysis), Application (Bioprocess (Pharmaceutical Companies, Research Institutes)) - Global Forecast to 2023

  The global desalting and buffer exchange market is projected to reach USD 1,094.8 million by 2023 from USD 679.8 million in 2018, at a CAGR of 10.0%. The base year considered for the study is 2017, and the market forecast is provided for 2018–2023. Growth in this market will largely be driven by increasing demand for mAbs, increasing R&D expenditure by pharmaceutical and biopharmaceutical companies, and growing focus on proteomic and genomic research. Key players in the global desalting and buffer exchange market are Thermo Fisher Scientific (US), Merck (US), GE Healthcare (US), Danaher (US), and Sartorius (Germany).

  • Published: October 2018
  • Price: $ 5650
  • TOC Available:

• Viral Clearance Market by Application (Recombinant Proteins, Blood, Vaccines), End User (Pharmaceutical & Biotechnology Companies, CROs), Method (Viral Removal (Chromatography, Nanofiltration), Viral Inactivation (Low pH)) - Global Forecasts to 2023

  The global viral clearance market is expected to reach USD 724.5 million by 2023 from an estimated USD 271.2 million in 2018, at a CAGR of 21.7% during the forecast period. The growth of this market is primarily driven by factors such as the growth in the pharmaceutical and biotechnology industries, increasing number of new drug launches, R&D investments in life science, advancements in nanofiltration technology, and high incidence and large economic burden of chronic diseases. The key players in the global viral clearance market are Wuxi Biologics (Cayman) (China), Merck KGaA (Germany), Charles River Laboratories International Inc. (US), and Texcell Inc. (France), Kedrion (Italy), Vironova Biosafety (Sweden), Clean Cells (France), BSL BIOSERVICE Scientific Laboratories Munich GmbH (Germany), and ViruSure GmbH (Austria).

  • Published: September 2018
  • Price: $ 5650
  • TOC Available:

• Cell Viability Assays Market by Product (MTT Assay, XTT Assay, Calcein, Resazurin, Flow Cytometry, Spectrophotometer), Cell Type (Human, Animal, Microbial), Application (Basic Research, Stem Cell, Discovery & Development) - Global Forecast to 2023

  The global cell viability assays market is projected to reach USD 4.16 billion by 2023 from USD 2.78 billion in 2018, at a CAGR of 8.4%. Factors contributing to the growth of this market include the rising incidence and prevalence of chronic and infectious diseases, growing availability of funds for research, rising demand for cell-based assays in research, and increasing focus on the development of cell-based therapeutics. The prominent players in the cell viability assays market are Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), Merck (Germany), GE Healthcare (US), BioTek Instruments (US), PerkinElmer (US), Promega Corporation (US), Biotium (US), Abcam plc (UK), Canvax (Spain), Abnova (Taiwan), G-Biosciences (US), Creative Bioarray (US), Danaher Corporation (US), and Becton, Dickinson and Company (US).

  • Published: September 2018
  • Price: $ 5650
  • TOC Available:

• Track etched Membrane Market by Product (Membrane Filter, Capsule & Cartridge Filter, Cell Culture Insert), Material (Polycarbonate, Polyimide), Application (Cell Biology, Microbiology, Analytical testing, Automotive), End User - Global Forecast to 2023

  The track etched membrane market is expected to reach USD 813.1 million by 2023 from USD 476.0 million in 2018, at a CAGR of 11.3% from 2018 to 2023. Key factors driving the growth of this market include increasing R&D spending in the pharmaceutical and biopharmaceutical industries and increasing purity requirements among end users of track etched membranes. However, the high cost of production and the limited supply of track etched Membranes are major factors that are expected to restrain the growth of this market during the forecast period. Key players operating in the global track etched membrane are GE Healthcare (US), Danaher (US), Corning (US), Merck (Germany), it4ip (Belgium), Sterlitech (US), Oxyphen (Switzerland), Sarstedt (US), BRAND GMBH (Germany), Sartorius (Germany), SABEU (Germany), Zefon International (US), GVS (Italy), Thermo Fisher Scientific (US), Eaton (Ireland), Greiner Bio-One (Austria), MACHEREY-NAGEL (Germany), Avanti Lipids Polar (US), SKC (US), Advantec (Canada), Avestin (Canada), Scaffdex (Finland), and Graver Technologies (US).

  • Published: September 2018
  • Price: $ 5650
  • TOC Available:

• Hydrophobic Interaction Chromatography Market by Product & Services (Resin, Columns (Empty, Prepacked), Buffer), Sample (Monoclonal Antibodies, Vaccines), End User (Pharmaceutical Companies, CROs & CMOs, Research Institutes) - Global Forecast to 2023

  The global hydrophobic interaction chromatography market is projected to reach USD 418.2 million in 2023 from USD 271.0 million in 2017, at a CAGR of 7.5%. The base year considered for the study is 2017, and the forecast for the market size is provided for the period between 2018 and 2023. In the current market scenario, there is a growing demand for hydrophobic interaction chromatography. The major factors driving the growth of this market are the increasing demand for monoclonal antibodies and increasing R&D expenditure in biopharmaceuticals. The key players in the global hydrophobic interaction chromatography market are GE Healthcare (US), Bio-Rad Laboratories (US), Sartorius (Germany), and Thermo Fisher Scientific (US).

  • Published: August 2018
  • Price: $ 5650
  • TOC Available:

• Protein Binding Assays Market by Technology (Equillibrium Dialysis, Ultrafiltration, Ultracentrifugation, Gel Filtration Chromatography), End User (Pharmaceutical & Biotechnology Companies, Contract Research Organization) - Global Forecast to 2023

  The major players operating in the global protein binding assay market are Thermo Fisher (US), HTDialysis (US), Merck (US), GE Healthcare (US), and Absorption Systems (US). The global protein binding market is projected to reach USD 425.7 million in 2023 from USD 256.1 million in 2018, at a CAGR of 10.7%. The growing number of drug discovery activities, the minimizing drug discovery and development costs, and the increase in pharmaceutical R&D expenditure are driving the growth of this market. The key players in the global protein binding assays market are HTDialysis (US), Thermo Fisher Scientific (US), Merck (Germany), and Sovicell (Germany).

  • Published: August 2018
  • Price: $ 5650
  • TOC Available:

• Microarray Analysis Market by Product & Service (Consumables, Instrument, Software, Services), Type (DNA, Protein Microarray), Application (Research), End User (Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies) - Global Forecast to 2023

  The global microarray analysis market is expected to reach USD 5.52 billion by 2023 from USD 3.82 billion in 2018, at a CAGR of 7.6%. The major factors driving the growth of this market are the increasing incidence of cancer, increasing funding for genomic and proteomic research, and growing application areas of microarrays. Key players in the microarray analysis market include Thermo Fisher Scientific, Inc. (US), Agilent Technologies, Inc. (US), Molecular Devices (US), PerkinElmer Inc. (US), Illumina, Inc. (US), GE Healthcare (US), and Bio-Rad Laboratories Inc. (US).

  • Published: August 2018
  • Price: $ 5650
  • TOC Available:

• Viral Vector Manufacturing Market by Type (Retrovirus, Gammaretrovirus, AAV), Disease (Cancer, Infectious Disease, Genetic Disorders), Application (Gene Therapy, Vaccinology), End User (Biotech companies, Research Institutes) - Global Forecast to 2023

  The global viral vector manufacturing market is projected to reach USD 815.8 million by 2023 from USD 327.8 million in 2018, at a CAGR of 20.0%. Some key factors driving market growth include the rising prevalence of target diseases and disorders, the availability of funding for gene therapy development, effectiveness of viral vectors in gene therapy delivery, and ongoing research into viral vector-based gene & cell therapies. Untapped potential in emerging markets is expected to offer lucrative growth opportunities for players in the viral vector manufacturing market. The major players in the global viral vector manufacturing market are Lonza (Switzerland), Merck (Germany), Oxford BioMedica (UK), CGT Catapult (UK), Cobra Biologics (UK), uniQure (Netherlands), FUJIFILM Diosynth Biotechnologies (US), Kaneka Eurogentec (Japan), and Spark Therapeutics (US).

  • Published: August 2018
  • Price: $ 5650
  • TOC Available:

• Peptide Synthesis Market by Product (Reagent, Synthesizer, Chromatography), Technology (Solid Phase, Liquid Phase, and Hybrid & Recombinant), End User (Pharmaceuticals & Biotechnology, CRO), and Region - Global Forecast to 2023

  The peptide synthesis market is projected to reach USD 426.4 million by 2023 from USD 310.5 million in 2018, at a CAGR of 6.5% during the forecast period. Factors such as the growing use of peptides in pharmaceutical drugs, increase in research activities and availability of funding for R&D, and the development of advanced peptide synthesizers are expected to drive the growth of the market. However, the lack of a unified set of regulations for therapeutic peptides is expected to restrain the growth of this market during the forecast period. The prominent players in the peptide synthesis market are GenScript Biotech Corporation (China), AAPPTec (US), Bachem (Switzerland), AnaSpec (US), Biotage (Sweden), CEM Corporation (US), Gyros Protein Technologies (Sweden), Advanced ChemTech (US), Merck KGaA (Germany) and New England Peptide, Inc (US). Product launches and agreements, partnerships and collaborations were the major strategies adopted by these payers to maintain their positions in the peptide synthesis market.

  • Published: July 2018
  • Price: $ 5650
  • TOC Available:

• Transfer Membrane Market by Type (PVDF, Nitrocellulose, Nylon), Transfer Method (Tank, Semi-dry, Dry), Application (Western, Northern, Southern Blot, Protein Sequencing), End user (Academia, Diagnolab, Pharmaceutical Companies) - Global Forecast to 2023

  The global transfer membrane market is expected to reach USD 187.9 million by 2023 from USD 174.8 million in 2018, at a CAGR of 1.5% during the forecast period. Factors such as increasing public and private funding for life science research, the significantly high prevalence of target diseases across the globe, and increasing R&D spending by pharmaceutical and biotechnology companies are expected to drive the growth of transfer membrane market. The key players in the transfer membrane market include Merck KGaA (US), Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), GE Healthcare (US), PerkinElmer (US), Pall Coporation (US), Advansta (US), GVS (Italy), Santa Cruz Biotechnology (US), Abcam (UK), ATTO Corporation (Japan), Carl Roth (Germany), Macherey-Nagel (Germany), Azure Biosystems (US), and Axiva Sichem Biotech (India), among others.

  • Published: June 2018
  • Price: $ 5650
  • TOC Available:

• Creatinine Measurement Market by Product (Kits, Reagents), Test Type (Jaffe method, Enzymatic creatinine method), Sample (Serum Creatinine, Urine) and End User (Hospitals, Diagnostic Laboratories), Region (North America, Europe) - Global Forecast to 2023

  The global creatinine measurement market is expected to reach USD 564.5 Million by 2023 from USD 377.2 Million in 2018, at a CAGR of 8.4%. The growth of this market is mainly driven by increasing incidence of renal disorders, growing incidence of other chronic disorders impacting renal function, rising awareness and adoption of preventive healthcare approaches, implementation of favorable government initiatives to promote renal health, rapid growth in the geriatric population, and increasing number of drug development initiatives. The creatinine measurement market is highly fragmented with the presence of several large as well as emerging players. Prominent players in this market include F. Hoffmann-la Roche Ltd (Switzerland)., Abbott Laboratories (US), Danaher Corporation (US), Thermo Fisher Scientific Inc (US), Siemens Healthineers (Germany), Randox Laboratories (UK)., Pointe Scientific, Inc (US), Sentinel Ch. Spa. (Italy), Diasys Diagnostic Systems GmbH (Germany), Dialab GmbH (Vienna), Diazyme Laboratories, Inc (US), Wako Pure Chemical Industries, Ltd. (Japan), Ortho Clinical Diagnostics (US), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China).

  • Published: June 2018
  • Price: $ 5650
  • TOC Available:

• Multiplex Assays Market by Product (Consumables, Instruments), Type (Nucleic Acid, Protein, Cell), Technology (Flow Cytometry, Luminescence), Application (R&D, Diagnosis), End User (Pharma & Biotech, Reference Laboratory, Hospital) - Global Forecast to 2023

  The global multiplex assays market is projected to reach USD 3.35 Billion in 2023 from USD 2.33 Billion in 2018, at CAGR of 7.5%. Multiplex assays enables the simultaneous detection of multiple analytes in a single run/cycle of the assay. The use of multiplex assays in Companion Diagnostics for increasing the safety & efficacy of therapies and the advantages of multiplex assays over conventional singleplex assays are driving the growth of the market. The key players in the global multiplex assays market are Luminex (US), Bio-Rad Laboratories (US), Becton Dickinson (US), Illumina (US), and Thermo Fisher Scientific (US).

  • Published: June 2018
  • Price: $ 5650
  • TOC Available:

• Gene Panel Market by Product & Service, Technique (Amplicon, Hybridization), Design (Predesign, Custom), Application (Cancer, Congenital Disease, Pharmacogenetics) & End User (Hospital, Research Center, Pharmaceutical Companies) - Global Forecast to 2023

  The global gene panel market is expected to reach USD 2.95 Billion by 2023 from USD 1.22 Billion in 2018, at a CAGR of 19.2%. The growth of this market is mainly driven by the increasing prevalence of chronic diseases, growing company initiatives, and rising adoption of gene panel owing to the benefits they offer. The gene panel market is fragmented, with the presence of several large as well as emerging players. Prominent players in the gene panels market include Illumina, Inc. (US), BGI (China), Agilent Technologies (US), Eurofins Scientific (US), QIAGEN (Germany), GENEWIZ, Inc. (US), Novogene Corporation (China), Personalis (US), Thermo Fisher Scientific (US), F. Hoffmann-La Roche AG (Switzerland), Integrated DNA Technologies (IDT) (US), GATC Biotech AG (GATC Biotech) (Germany), and ArcherDx (US). Players in this market are adopting various organic and inorganic strategies, such as product launches & upgradations, agreements, partnerships, joint ventures, collaborations, and acquisition to widen their product portfolios and expand their presence in the market.

  • Published: May 2018
  • Price: $ 5650
  • TOC Available:

• Specimen Validity Testing Market by Product (Reagent, Controls, Assay Kits, Disposables), Type (Laboratory, POC Testing), End User (Workplace, Drug Screening, Pain Management, Drug Rehabilitation Centers) - Global Forecast to 2023

  The global specimen validity testing market is projected to reach USD 1.49 Billion by 2023 from USD 1.10 Billion in 2018, at a CAGR of 6.3%. The growth of the market is primarily driven by the growth in drug screening market and increase in workplace drug testing. While the specimen validity testing market represents significant growth opportunities, market growth may be hindered due to the emergence of alternative drug screening tests. The specimen validity testing market is marked by the presence of several big and small players. Prominent players offering specimen validity testing products include Thermo Fisher Scientific (US), Sciteck, Inc. (US), American Bio Medica Corporation (ABMC), Alere [now a part of Abbott (US)], Express Diagnostics Int'l, Inc. (US), and Premier Biotech, Inc. (US). While, Laboratory Corporation of America Holdings (LabCorp) (US), Quest Diagnostics (US), Alere Toxicology (Alere) (US), ACM Global Laboratories (US), Clinical Reference Laboratory (CRL) (US), SureHire (Canada), and CannAmm (Canada) are some of the leading service providers.

  • Published: May 2018
  • Price: $ 5650
  • TOC Available:

• Neuroscience Antibodies & Assays Market by Product (Reagent (Media, Sera, Stain, Enzymes, Probe), Instruments), Technology (Immunoassay (Elisa), Molecular Diagnostics), Application (IVD) & End User (Research Institute, Hospital) - Global Forecast to 2023

  The global neuroscience antibodies and assays market is expected to reach USD 4.18 Billion by 2023 from USD 2.57 Billion in 2018, at a CAGR of 10.2%. Growth in this market is driven by the rising incidence of neurological diseases, increasing investments in neuroscience research, and growth in the pharmaceutical and biotechnology industries. The neuroscience antibodies and assays market is fragmented, with the presence of several large as well as emerging players. In 2017, Thermo Fisher Scientific (US), Abcam (UK), Bio-Rad (US), and Merck KGaA (Germany) were the leading players in the neuroscience antibodies and assays market. Other major players include BioLegend (US), Cell Signaling Technology (US), F. Hoffmann-La Roche (Switzerland), GenScript (China), Rockland Immunochemicals (US), Santa Cruz Biotechnology (US), Siemens (Germany), and Tecan (Switzerland).

  • Published: May 2018
  • Price: $ 5650
  • TOC Available:

• Stem Cell Banking Market by Source (PSC, BMSC, ADSC, hESC, DPSC, NSC), Service Type (Sample Processing, Analysis, Collection, Storage), Application (Personalized Storage, Clinical (Autoimmune, Hematopoietic Disorders), Research) - Global Forecasts to 2023

  The global stem cell banking market is projected to reach USD 9.30 Billion by 2023 from USD 6.28 Billion in 2018, at a CAGR of 8.2%. Factors such as public awareness related to the therapeutic potential of stem cells; development of novel technologies for stem cell preservation, processing, and storage; rising number of hematopoietic stem cell transplantations (HSCTs); and increasing number of stem cell-based research are driving the growth of the market. As of 2017, major players in the global stem cell banking market include Cord Blood Registry (CBR) Systems (US), Cordlife Group Limited (Singapore), Cryo-Cell International (US), ViaCord (US), Cryo-Save AG (Netherlands), LifeCell International (India), StemCyte (US), Global Cord Blood Corporation (China), Smart Cells International (UK), Vita34 AG (Germany), and CryoHoldco (Mexico).

  • Published: May 2018
  • Price: $ 5650
  • TOC Available:

• In Vitro Lung Model Market by Type (2D, 3D (In-house, Commercial)), Application (Drug Screening, Toxicology, 3D Model Development, Basic Research, Physiologic Research, Stem Cell Research, Regenerative Medicine) - Global Forecasts to 2023

  The lung in vitro models market is projected to reach USD 427.4 Million by 2023 from USD 190.5 Million in 2018, at a CAGR of 17.5%. The key factors driving the growth of this market include growing focus on developing alternatives for animal testing models, advancements in Cell Culture technologies, and the development of new 3D in vitro models. The major players in the Lung in vitro models market include Epithelix (Switzerland), MatTek Corporation (US), Lonza (Switzerland), ATCC (US), InSphero (Switzerland), Emulate (US), AlveoliX (Switzerland), Oncotheis (Switzerland), Insphero (Switzerland), TissUse (Switzerland), Mimetas (Netherlands), and CN Bio Innovations (UK).

  • Published: April 2018
  • Price: $ 11000
  • TOC Available:

• Stem Cell Assay Market by Type (Viability, Purification, Identification), Cell Type (Mesenchymal, iPSCs, HSCs, hESCs), Product & Service (Instruments, Kits), Application (Regenerative Medicine, Clinical Research), End User - Global Forecast to 2023

  The global stem cell assay market is expected to reach USD 1,978.7 Million by 2023 from USD 791.9 Million in 2018, at a CAGR of 20.1%. The market growth is primarily driven by increasing government and private funding for stem cell research and technological innovations in stem cell research-based instruments. Key players in the stem cell assay market include Thermo Fisher Scientific (US), GE Healthcare (US), Merck (Germany), Bio-Rad Laboratories (US), Promega Corporation (US), Agilent Technologies (US), PerkinElmer (US), Miltenyi Biotec (Germany), Cell Biolabs (US), HemoGenix (US), STEMCELL Technologies (Canada), Bio-Techne Corporation (US), and Cellular Dynamics International (US).

  • Published: March 2018
  • Price: $ 5650
  • TOC Available:

• Humanized Mouse and Rat Model Market by Type (Genetic, Cell-Based (CD34, PBMC, BLT)), Application (Neuroscience, Hematopoesis, Oncology, Immunology & Infectious Diseases) & End User (Pharmaceutical & Biotechnology Companies, CRO)) - Global Forecast to 2022

  The humanized mouse models market is projected to reach USD 128.9 Million by 2022 from USD 80.3 Million in 2017, at a CAGR of 9.9% during the forecast period. The humanized rat models market is expected to reach USD 8.9 Million by 2022 from USD 5.9 Million in 2017, at a CAGR of 8.4% during the forecast period. The key factors boosting market growth are increasing number of R&D activities in pharmaceutical and biotechnology companies, increasing number of research activities involving humanized models, continuous support in the form of investments and grants from the government and private sectors, and growing demand for personalized medicine. The major market players in the humanized mouse models market include The Jackson Laboratory (US), Taconic Biosciences, Inc. (US), Horizon Discovery Group plc (UK), genOway, S.A. (France), Charles River Laboratories (US), Harbour Antibodies BV (China), Hera BioLabs (US), Vitalstar Biotechnology Co., Ltd. (China), inGenious Targeting Laboratory (US), AXENIS S.A.S (France), Crown Bioscience, Inc. (US), Transgenic, Inc. (Japan), and Champions Oncology, Inc. (US). The major players in the humanized rat models market include Horizon Discovery Group plc (UK), Hera BioLabs (US), and Yecuris Corporation (US).

  • Published: March 2018
  • Price: $ 5650
  • TOC Available:

• Creatinine Assay Kits Market by Type (Jaffe's Kinetic Test, Creatinine-PAP, and ELISA), Sample (Blood, Serum, Urine, Saliva, CSF, Tissue Homogenate, Sweat) and Region (North America, Europe, Asia and RoW) - Global Forecast to 2022

  The global creatinine assay kits market is expected to reach USD 245.4 Million by 2022 from USD 189.6 Million in 2017, at a CAGR of 5.3%. The growth of this market is mainly driven by the increasing incidence of renal disorders, growing incidence of other chronic disorders impacting renal function, growing awareness and adoption of preventive healthcare, favourable government initiatives to promote renal health, rapid growth in the geriatric population, and advancements in biomedical research pertaining to kidney disorders and availability of funding. The creatinine assay kits market is highly fragmented with the presence of several large as well as emerging players. Prominent players in this market include Thermo Fisher Scientific (US), Merck (Germany), Abbott Laboratories (US), Abcam (UK), Quidel (US), Enzo Life Sciences (US), Cayman Chemical (US), Crystal Chem (US), Cell Biolabs (US), Genway Biotech (US), BioAssay Systems (US), Wako Pure Chemical Industries (Japan), Tulip Diagnostics (India), BioVision (US), and Arbor Assays (US).

  • Published: March 2018
  • Price: $ 14000
  • TOC Available:

• Cell Harvesting Market by Type (Manual, Automated), Application (Biopharmaceutical, Stem Cell Research), End User (Biotechnology, Biopharmaceutical Companies, Research Institute), and Region (North America, Europe, APAC, Row) - Global Forecasts to 2023

  Cell harvesting is the process of harvesting cells from the culture media during upstream and downstream bioprocessing. Cell harvesters are used extensively for the cell harvesting process and are compatible with a wide range of assays. The global cell harvesting market is expected to reach USD 324.5 Million by 2023 from USD 213.8 Million in 2018, at a CAGR of 8.7%. Rising investments in Regenerative Medicine and cell-based research, growth of the biopharmaceutical and biotechnology industry, and increasing incidence of chronic and infectious diseases are the major driving factors for this market. Some of the major players operating in the cell harvesting market are PerkinElmer (US), Brandel (US), TOMTEC (US), Cox Scientific (UK), Connectorate (Switzerland), Scinomix (US), ADSTEC (Japan), and Terumo BCT (a part of Terumo Corporation) (Japan).

  • Published: March 2018
  • Price: $ 5650
  • TOC Available:

• Thyroid Function Test Market by Type (TSH Tests, T4 Tests, T3 Tests), End User (Hospitals, Diagnostic Laboratories, Research Laboratories & Institutes), and Region (North America, Europe, APAC, LATAM, and MEA) - Global Forecast to 2022

  The global thyroid function tests market is projected to USD 1.68 Billion by 2022 from an estimated USD 1.26 Billion in 2017, at a CAGR of 5.9% during the forecast period. This growth can be attributed to factors such as increasing incidence of thyroid disorders, increasing awareness about thyroid disorders, increasing prevalence of lifestyle diseases, rising geriatric population, and increasing consumption of alcohol and tobacco. The prominent players in the global thyroid function tests market include Thermo Fisher (US), Abbott (US), Roche (Switzerland), DiaSorin (Italy), Danaher (US), Kronus (US), Merck (Germany), Cortez Diagnostics (US), bioMérieux (France), Qualigen (US), and Autobio Diagnostics (China).

  • Published: February 2018
  • Price: $ 5650
  • TOC Available:

• Organs-on-chips Market by Type (Liver, Kidney, Lung, Heart, Intestines, Gut), Offering (Product, Service), Application (Toxicity testing, Physiological model), End User (Academic, Research Institute, Pharma companies) - Global Forecast to 2022

  The organs-on-chips market is expected to reach USD 45.6 Million by 2022 from USD 9.6 Million in 2017, at a CAGR of 36.6%. The growth of this market is mainly driven by the growing focus on developing alternatives for animal testing models, significant increase in research funding and venture capital investments for the development of organs-on-chips, technological advancements and new products launches, growing number of partnerships and collaborations between pharmaceutical companies and organs-on-chips manufacturers, and growing need for early detection of drug toxicity to minimize financial losses due to late stage drug failure. The organs-on-chips market is emerging and high growth potential market with the presence of several small players and startups firms. Some of the players in the organs-on-chips market include Emulate (US), CN Bio (UK), TissUse (Germany), Mimetas (Netherlands), InSphero (Switzerland), Ascendance Bio (US), Kirkstall (UK), HUREL (HUREL) (US), SynVivo (US), AxoSim (US), and Nortis (US).

  • Published: January 2018
  • Price: $ 5650
  • TOC Available:

• Epigenetics Market by Product (Kit, Enzymes, Reagent, NGS, Mass Spectrometer, PCR, Bioinformatics), Application (Oncology, Cardiology, Immunology), Technology (DNA Methylation, Histone Modification), End User (Academic, CRO) - Global Forecast to 2022

  The global epigenetics market is projected to reach USD 1,605.7 Million by 2022 from USD 854.0 Million in 2017, at a CAGR of 13.5% during the forecast period. Market growth can be attributed to the decreasing sequencing costs, increase in research activities, availability of funding for epigenetics research, and rising prevalence of cancer. The global epigenetics market is characterized by a large number of players. The prominent players in this market are Illumina (US), Thermo Fisher (US), Diagenode (Belgium), QIAGEN (Netherlands), Merck Millipore (US), Abcam (UK), Active Motif (US), New England Biolabs (US), Agilent (US), Zymo Research (US), PerkinElmer (US), and Bio-Rad (US).

  • Published: October 2017
  • Price: $ 5650
  • TOC Available:

• Human Identification Market by Product & Services (Consumables, Instruments, Software), Technology (PCR, Capillary Electrophoresis, NGS, Microarray), Application (Forensic, Paternity Testing), End User (Forensic Laboratories) - Global Forecast to 2022

  Human identification is widely used in forensics, paternity testing, disaster victim identification, and anthropology with DNA analysis/profiling being a key tool in this sector. The global human identification market is expected to reach USD 1740.2 Million by 2022 from USD 928.0 Million in 2017, at a CAGR of 13.4%. Technological advancement, government initiatives for forensic programs, and focus of market players on expanding their reach are the major driving factors for this market. Some of the major players operating in the human identification market Thermo Fisher Scientific Inc. (US), Promega Corporation (US), QIAGEN N.V. (Netherlands), Illumina Inc. (US), GE Healthcare (US), and Agilent Technologies Inc. (US).

  • Published: September 2017
  • Price: $ 5650
  • TOC Available:

• Next-Generation Sequencing (NGS) Services Market by Type (Targeted, RNA-Seq, Exome, De Novo), Technology (Sequencing by Synthesis, Ion semiconductor, SMRT, Nanopore), & Application (Diagnostics, Oncology, Drug Discovery, Agriculture) - Forecasts to 2022

  The global next-generation sequencing (NGS) services market is projected to reach USD 2,748.6 Million by 2022 from USD 1,059.2 Million in 2017; growing at a CAGR of 21.0%. As of 2016, the major NGS services providers in the global NGS services market included BGI (China), Eurofins Scientific SE (Luxembourg), PerkinElmer, Inc. (U.S.), QIAGEN (Germany), Macrogen Inc. (South Korea), GENEWIZ, Inc. (U.S.), Illumina, Inc. (U.S.), Novogene Corporation (China), GATC Biotech AG (Germany), DNA Link, Inc (South Korea), Genotypic Technology Pvt Ltd (India), LGC Limited (U.K.), Wuxi Apptech Co. Ltd. (China), Zymo Research Corp (U.S.), Source BioScience (U.K.), and Personalis, Inc. (U.S.) among others.

  • Published: August 2017
  • Price: $ 5650
  • TOC Available:

• Biobanking Market by Product and Service(Equipment, Consumables, Services, Software), Sample Type (Blood Products, Human Tissues, Cell Lines, Nucleic Acids), Application( Regenerative Medicine, Life Science, Clinical Research) - Global Forecast to 2022

  The biobanking market is expected to reach USD 2.69 billion by 2022 from USD 1.72 billion in 2016 at a CAGR of 7.8%. The base year for this study is 2016. The equipment segment is estimated to account for the largest share of the biobanking market in 2017. This is primarily attributed to the increasing number of biobanks and rising number of biosamples around the world, due to which the demand for equipment remains high.

  • Published: August 2017
  • Price: $ 5650
  • TOC Available:

• Competent Cells Market by Type (Chemically, Electrocompetent), Application (Subcloning, Phage Display Library Production, Unstable DNA Cloning, High-Throughput Cloning, Mutagenesis), End User (Pharmaceutical Companies, Academia) - Global Forecast to 2022

  The competent cells market is expected to reach USD 2.22 Billion by 2022 from USD 1.37 Billion in 2017, at a CAGR of 10.2% from 2017 to 2022. Key players operating in the competent cells market include Merck KGaA (Germany), Promega Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S), New England Biolabs (U.S.), Takara Bio (Japan), Agilent Technologies (U.S.), Lucigen (Epicenter) (Illumina) (U.S.), QIAGEN N.V. (Germany), OriGene Technologies (U.S.), Bioline (U.K.), Zymo Research (U.S.), Beijing TransGen Biotech Co., Ltd. (China), Source BioScience (U.K.), IBA GmBH (Germany), Genewiz (U.S.), BioDynamics Laboratory, Inc. (Japan), GCC Biotech (India), SMOBIO Technology (Taiwan), GeneScript Corporation (U.S.), Bio-Rad Laboratories (U.S.), Life Technologies (India) Pvt. Ltd., Cell Applications, Inc. (U.S.), Delphi Genetics (Belgium), Scarab Genomics, LLC (U.S.), and Yeastern Biotech Co., Ltd. (Taiwan).

  • Published: July 2017
  • Price: $ 5650
  • TOC Available:

• Cellular Health Screening/ Health Testing Market by Type (Single (Telomere, Oxidative Stress, Inflammation, Heavy Metal), Multitest), Sample (Blood, Saliva, Serum, Urine), Collection Site (Home, Office, Hospital, Diagnostic Labs), and Region - Global Forecast to 2022

  The global cellular health screening market is expected to reach USD 3.42 Billion by 2022 from USD 2.12 Billion in 2017, at a CAGR of 10.0% during the forecast period. The global cellular health screening market is highly competitive with the presence of several small and big players. Prominent players in the cellular heath screening market include Genova Diagnostics (U.S.), Telomere Diagnostics (U.S.), Life Length (Spain), Quest Diagnostics (U.S.), Repeat Diagnostics (Canada), SpectraCell Laboratories (U.S.), Zimetry LLC (U.S.), Cell Science Systems (U.S.), Titanovo, Inc. (U.S.), Segterra, Inc. (U.S.), LabCorp Holdings (U.S.), BioReference Laboratories (U.S.), Immundiagnostik AG (Germany), DNA Labs (India), and Cleveland HeartLab, Inc. (U.S.).

  • Published: July 2017
  • Price: $ 9500
  • TOC Available:

• Preimplantation Genetic Testing Market by Type (Genetic Diagnosis/Genetic Screening), Technology (NGS, PCR, FISH, CGH, SNP), Products & Services, Application (Aneuploidy, Translocations), End User (Fertility Clinics, Research) - Forecast to 2022

  The global preimplantation genetic testing market is expected to reach USD 541.8 Million by 2022 from USD 336.4 Million in 2017, at a CAGR of 10.0%. Other prominent players in the market are Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Beijing Genomics Institute (BGI) (China), Abbott Laboratories (U.S.), Natera, Inc. (U.S.), Genea Limited (Australia), Rubicon Genomics, Inc. (U.S.), and Oxford Gene Technology (U.K.), among others.

  • Published: July 2017
  • Price: $ 5650
  • TOC Available:

• Microbiome Sequencing Services Market by Technology (Sequencing by Synthesis), Application (RNA Sequencing), Research Type (Outsourcing), Laboratory Type (Wet Lab, Dry Lab), End User (Pharmaceutical & Biotechnology), Other Technologies - Forecast to 2021

  The global microbiome sequencing services market is poised to reach USD 1,424.7 Million by 2021 from USD 538.0 Million in 2016, at a CAGR of 21.5% from 2016 to 2021. In this report, the global microbiome sequencing services market is broadly segmented by technology, application, research type, laboratory type, end user, and region. On the basis of technology, the market is divided into sequencing by synthesis (SBS), sequencing by ligation (SBL), pyrosequencing, sanger sequencing, and other technologies (such as Omic technologies). The sequencing by synthesis segment is expected to grow at the highest CAGR of the market in 2016.

  • Published: May 2017
  • Price: $ 5650
  • TOC Available:

• Protein Assays Market by Product (Reagent, Kit, Instruments), Type (Dye Binding, Test Strip), Application (Drug Discovery, Disease Diagnosis), Technology (Colorimetric, Fluorescence), End User (Pharmaceutical, Clinical Lab) - Global Forecasts to 2022

  The protein assays market is expected to reach USD 2.41 Billion by 2022 from USD 1.42 Billion in 2017, at a CAGR of 11.1%. The increasing pharmaceutical & biotech R&D expenditure and the favorable government funding scenario for Proteomics research are the major factors that are expected to drive the growth of the protein assays market during the forecast period.

  • Published: May 2017
  • Price: $ 5650
  • TOC Available:

• Cell Signaling Market by Type (Endocrine, Paracrine), Pathway (Akt, AMPK, Hedgehog, Notch), Product (Consumables, Instruments), Technology (Flow Cytometry, ELISA, Mass Spectrometry) & Application (Research, Cancer, Immunology) - Global Forecast to 2022

  The cell signaling market is projected to reach USD 3.51 Billion by 2022 from USD 2.53 Billion in 2017, at a CAGR of 6.8%. The term “cell signaling” is used to define the complex interactive system of signals that regulates and mediate various cellular responses in the human body.

  • Published: May 2017
  • Price: $ 5650
  • TOC Available:

• High-Resolution Melting Analysis Market by Product (Supermix Reagent, RT PCR Instrument, Software), Application (SNP Genotyping, Mutation Discovery, Epigenetics), Enduser (Research Laboratories, Hospital, Diagnostic Center) - Global Forecast to 2021

  The global high-resolution melting analysis market is expected to reach USD 302.1 Million by 2021 from USD 259.4 Million in 2016, at a CAGR of 3.1% during the forecast period of 2016 to 2021. Rising prevalence of infectious diseases and genetic disorders; increasing public-private investments, funds, and grants for research on genetic analysis technologies; and advantages of HRM over other genotyping technologies are the major factors driving market growth.

  • Published: April 2017
  • Price: $ 5650
  • TOC Available:

• High Content Screening Market by Product (Cell Imaging & Analysis System, Flow Cytometry, Consumable, Software, Service) Application (Primary & Secondary Screening, Toxicity Studies, Target Identification & Validation), End User - Global Forecast to 2022

  The global high-content screening market is projected to reach USD 909.0 Million by 2022 at a CAGR of 10.3% during the forecast period. The factors expected to drive the growth of the market are growth in funding for cellular research, cost containment in pharma R&D, and technological advancements in HCS solutions. The rapid growth in developing countries across APAC is also expected to provide an opportunity for revenue generation in the market. However, the high cost of HCS instruments and the dearth of knowledgeable and skilled personnel for the operation of the instruments are expected to restrain the market growth.

  • Published: April 2017
  • Price: $ 5650
  • TOC Available:

• High Throughput Process Development Market by Product (Consumables (Minicolumn, Mini Bioreactor), Instruments), Services, Software, Molecule Type (mAB), Technology (Affinity Chromatography), End User (Biopharmaceutical) - Global Forecast to 2021

  The global high throughput process development market is expected to reach USD 415.5 Million in 2021 from USD 212.1 Million in 2016, at a CAGR of 14.4% from 2016 to 2021. Major players operating in the high throughput process development market include Danaher (US), GE Healthcare (US), Agilent Technologies (US), Merck Millipore (Germany), and Thermo Fisher Scientific (US).

  • Published: April 2017
  • Price: $ 5650
  • TOC Available:

• Pharmaceutical Filtration Market by Product (Membrane Filters, Single-Use Systems), Technique (Microfiltration, Ultrafiltration), Application (Final Product Processing, Raw material), Scale of Operation (Manufacturing, Pilot, R&D) - Global Forecast to 2021

  The global pharmaceutical filtration market is projected to reach USD 22.71 Billion by 2021 from USD 13.73 Billion in 2016, at a CAGR of 10.6% during the forecast period. Growth in the pharmaceutical filtration market is primarily driven by factors such as growth in the production of biopharmaceuticals, technological advancements in filtration equipment, and rapid growth in generics production. Other factors supporting market growth include an increase in R&D spending by biopharmaceutical companies leading to a strong biologics pipeline and government mandates to have a clean and safe research and manufacturing environment.

  • Published: March 2017
  • Price: $ 5650
  • TOC Available:

• Downstream Processing Market by Technique (Separation, Concentration, Purification), Product (Chromatography Column & Resin, Filter, Single use), Application (Mab Production), End User (Contract Manufacturing Organization) - Global Forecast to 2021

  The global downstream processing market is projected to reach USD 22.03 Billion by 2021 from USD 10.32 Billion in 2016, at a CAGR of 16.4% from 2016 to 2021. In this report, the global downstream processing market is broadly segmented on the basis of technique, product, application, end user, and region.

  • Published: March 2017
  • Price: $ 5650
  • TOC Available:

• Sterility Testing Market by Product (Instruments, Services, Kits and Reagents), Test (Membrane Filtration Sterility Testing, Direct Inoculation Sterility Testing), Application (Pharmaceutical & Biotechnology, Medical Devices) - Global Forecasts to 2021

  The sterility testing market was valued at USD 528.0 Million in 2016 and poised to grow at a CAGR of 12.3% between 2016 and 2021, to reach USD 941.0 Million in 2021. Sterility testing is conducted for the presence or absence of viable microorganisms capable of developing and multiplying under favorable conditions. Sterility testing is used by pharmaceutical & biotechnological companies and medical devices companies to ensure the absence of contaminants in biologics and medical devices.

  • Published: March 2017
  • Price: $ 5650
  • TOC Available:

• Top 10 Bioprocess Technology Market by Cell Culture, Cell Expansion, Cell Counting, Cell Line Development, Flow Cytometry, Single-Use Bioprocessing, Biologics Safety Testing, Tangential Flow Filtration, Virus Filtration & Region - Forecast to 2021

  The global top 10 bioprocess technology market is expected to USD 71.03 Billion by 2021 from USD 39.30 Billion in 2016, at a CAGR of 12.4% between 2016 and 2021. Growth in the biopharmaceutical industry, increase in R&D spending, rising demand for vaccine production, and technological advancements form important growth drivers for this market. On the other hand, stringent regulatory policies and high cost of instruments are restraining market growth for bioprocess technologies.

  • Published: January 2017
  • Price: $ 5650
  • TOC Available:

• Top 10 Cellular Analysis Market by Technology (Imaging, PCR, Flow Cytometry, High-content Screening, Blotting, Spectrophotometry), Application (Stem Cell, Cancer, Tissue Engineering) & End User (Biotechnology, Research) - Global Forecast to 2021

  The top 10 cellular analysis market is expected to reach USD 41.34 Billion by 2021 from USD 28.66 Billion in 2016, at a CAGR of 7.6% during the forecast period. Cellular analysis is used for cell identification, cell interaction, cell viability, cell proliferation, cell structure study, cell signaling/cell transduction, target identification & validation, cell counting, and quality control. Currently, cellular analysis technologies are used in various phases of the drug discovery process, cancer diagnosis (oncology), blood cell analysis, toxicity testing, personalized medicine, pathogen testing, and other applications.

  • Published: January 2017
  • Price: $ 5650
  • TOC Available:

• Transfection Reagents and Equipment Market by Method (Biochemical (Calcium Phosphate, Lipofection, Dendrimers), Physical (Electroporation, Nucleofection), Viral)), Application (Biomedical, Protein Production), End User - Global Forecast to 2021

  The global transfection reagents and equipment market includes forecast from 2016 to 2021. This market is expected to reach USD 1.02 Billion by 2021 from USD 715.4 Million in 2016, at a CAGR of 7.5% during the forecast period. This growth can be attributed to factors such as advancements in transfection technology, global alliances among leading research institutes to trigger drug discovery, increase in R&D spending and research activities by pharmaceutical and biotechnology companies, increase in demand for synthetic genes, and rising incidence of cancer. Moreover, development of large scale transfections, rising demand of protein therapeutics, and emerging markets across India and China are likely to create opportunities for players operating in the market.

  • Published: January 2017
  • Price: $ 5650
  • TOC Available:

• First
• Previous
• 3
• 4
• Next
• Last